Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Wait Out The GLP-1 Storm - Buy The Hims And Hers Post-Earnings Dip
01:02pm, Tuesday, 05'th Aug 2025
Hims and Hers faced a short-term revenue dip due to regulatory changes and GLP-1 customer offboarding, but core growth remains strong. Subscriber numbers surged 31% quarter-over-quarter, and product d
Inspire Medical Systems Crashes 32% As Eli Lilly's GLP-1 Weighs On Guidance
09:30am, Tuesday, 05'th Aug 2025
Inspire Medical Systems crashed Tuesday after the maker of implantable sleep apnea devices called out GLP-1 drugs for weighing on sales.
GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly
09:09am, Tuesday, 05'th Aug 2025
Novo Nordisk's share price collapse is an overreaction; the market underestimates its robust pipeline and continued double-digit growth potential. The GLP-1 obesity drug market is massive and supports
Will GLP-1 Demand Drive MCK's Top Line This Earnings Season?
08:41am, Tuesday, 05'th Aug 2025
MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.
Hims & Hers: Buy The Core Engine, Not The Headline
08:15am, Tuesday, 05'th Aug 2025
Hims & Hers Health's Q2 revenue miss and decelerating growth triggered a stock drop, but core business ex-GLP-1 remains robust with strong subscriber growth. Profitability is improving, with adjusted
- 13-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of two oral formulations of ASC30, a once-daily tablet, in 125 participants with obesity or overwei
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
08:00pm, Monday, 04'th Aug 2025
SAN FRANCISCO and SUZHOU, China , Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results?
01:11pm, Monday, 04'th Aug 2025
COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.
Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated
West Pharmaceutical: Q2 Earnings Suggest Recovery
12:20pm, Wednesday, 30'th Jul 2025
West Pharmaceutical Services, Inc.'s Q2 results signal a return to growth, driven by strong demand for high-value products and GLP-1 agonist components. I am revamping my bullish thesis: GLP-1 drugs n
Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?
09:00am, Wednesday, 30'th Jul 2025
The sharp Novo Nordisk A/S stock drop reflects real concerns: slowing demand, CEO transition, rising competition, and macro headwinds. GLP-1 hype is fading as insurance coverage wanes, compounded gene
Hims & Hers Data Shows Personalized GLP-1 Plans Drive Real Weight Loss, Few Side Effects, and Strong Adherence to Care
09:00am, Tuesday, 29'th Jul 2025
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today released new data showing that its personalized, digital-first
Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study
09:25am, Monday, 28'th Jul 2025
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
09:25am, Monday, 28'th Jul 2025
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus® DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus® DehydraTECH-GLP
Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might
09:16am, Saturday, 26'th Jul 2025
GLP-1 agonist drugs like Zepbound and Mounjaro from drugmaker Eli Lilly (LLY 0.84%) continue to rise in popularity as people are hopeful about the weight loss they can achieve with their help. But a g
